Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalbuphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 10/20 | 1.00 |
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalbuphine SCHEMBL4138643 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL3118641 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL3118636 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL12945211 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL10103725 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL13225650 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL19199045 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL16310791 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL17168336 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL21090866 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660296-B2 | Treatment of chronic cough, breathlessness and dyspnea | Trevi Therapeutics, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| US-10736889-B2 | Method of treating dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180185355-A1 | Method of Treating Dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-07-05 | — | — | US | disclosed |
| US-20180185355-A1 | Method of Treating Dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-07-05 | — | — | US | disclosed |
| US-9932349-B2 | 8-carboxamido-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170216279-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-08-03 | — | — | US | disclosed |
| US-20170216279-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-08-03 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| US-20100190817-A1 | LARGE SUBSTITUENT, NON-PHENOLIC AMINE OPIOIDS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2010-07-29 | — | — | US | disclosed |
| EP-2206498-A1 | Mixed ORL1/[mu] agonists for treating pain | Grünenthal GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-7557119-B2 | analgesics, antidiarrheal agents, anticonvulsants, antitussives, anti-addiction; 8-Substituted-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048447-A1 | METHOD FOR DECREASING OPIOID METABOLISM | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | GRUNENTHAL GMBH (DE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | GRUNENTHAL GMBH (DE) | 2008-05-29 | — | — | US | disclosed |
| WO-2008040481-A1 | MIXED ORL 1/μ AGONISTS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | disclosed |
| US-20070238748-A1 | Methods for Treating Diseases with 4-Hydroxybenzomorphans | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070021457-A1 | analgesics, antidiarrheal agents, anticonvulsants, antitussives, anti-addiction; 8-Substituted-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 5/4885 |
| US-20070021457-A1 | analgesics, antidiarrheal agents, anticonvulsants, antitussives, anti-addiction; 8-Substituted-2,6-methano-3-benzazocines | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRK1 2/4885OPRD1 5/4885 |
| US-20180185355-A1 | Method of Treating Dyskinesia | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 2/4885 |
| US-11660296-B2 | Treatment of chronic cough, breathlessness and dyspnea | CCL11, NPPA, ELANE | OPRM1 130/4885OPRK1 49/4885OPRD1 107/4885 |
| US-10736889-B2 | Method of treating dyskinesia | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRK1 2/4885OPRD1 3/4885 |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRD1 4/4885 |
| US-20090048447-A1 | METHOD FOR DECREASING OPIOID METABOLISM | OPRM1, OPRK1, CYP3A43 | OPRM1 1/4885OPRK1 2/4885OPRD1 5/4885 |
| US-20100190817-A1 | LARGE SUBSTITUENT, NON-PHENOLIC AMINE OPIOIDS | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRK1 1/4885OPRD1 3/4885 |
| US-20070238748-A1 | Methods for Treating Diseases with 4-Hydroxybenzomorphans | TPMT, HTR3C, PYGL | OPRM1 65/4885OPRK1 11/4885OPRD1 78/4885 |
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | HRH4, HRH2, HRH3 | OPRM1 8/4885OPRK1 27/4885OPRD1 38/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 5/4885 |
| US-20170216279-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.